Skip to main content

Separation of Factor V Leiden Molecule, a Mutated Form of Factor V, from Plasma of Homozygous Patient

  • Conference paper
Oxygen Transport to Tissue XXIX

Part of the book series: Advances In Experimental Medicine And Biology ((AEMB,volume 614))

  • 2024 Accesses

Abstract

Factor V (FV) is a coagulant in plasma. The FV molecule consists of a heavy chain and a light chain, and Factor V Leiden (FVL) is mutated FV at a single amino acid in the heavy chain. FVL patients are in a dangerous hyper-coagulation state in their body. Current FVL diagnosis is done by DNA analysis, which is expensive and time consuming. Our group has been developing a real-time, cost effective immuno-optical biosensor for FVL diagnosis. For the sensor development, pure FVL, which is not currently available, is needed. Here, we have attempted FVL purification from FVL patient’s plasma. Since plasma contains many proteins and some proteins are structurally homologous to FV, the purification must be done by a very specific method, such as immuno-affinity chromatography. However, an antibody that does not react with FV is not currently available. Because the mutation is in the heavy chain and the amino acid sequence of the light chain of FVL is identical to that of FV, antibodies generated against the light chain of FV were tested for purifying FVL. Plasma was obtained from a homozygous FVL patient. First, the plasma was pretreated by barium citrate and polyethylene glycol 6000, to remove the vitamin K-dependent proteins, alpha globulins, and other smaller than 6 kDa molecular weight proteins. The yield in the process was 54%. Immuno-affinity purification of FVL from patient plasma was then performed using an anti-FV light chain antibody immobilized CNBr-Sepharose, and the purification yield was 25%. In summary, the antibody against the light chain of FV was able to purify the single point mutated form of FV (FVL) from plasma with an overall yield of 14%. The same principle can probably be used for purification of the other single point mutated proteins.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. C. T. Esmon, The subunit structure of thrombin-activated factor V: Isolation of activated factor V, separation of subunits, and reconstitution of biological activity. J. Biol. Chem. 254, 964–973 (1979).

    PubMed  CAS  Google Scholar 

  2. W. H. Kane, P. W. Majerus, Purification and characterization of human coagulation factor V. J. Biol. Chem. 256, 1002–1007 (1981).

    PubMed  CAS  Google Scholar 

  3. B. Dahlback, Human coagulation factor V purification and thrombin-catalyzed activation. J. Clin Invest. 66, 583–591 (1980).

    Article  PubMed  CAS  Google Scholar 

  4. J. Rosing, and G. Tans, Factor V, Int J. Biochem.29, 1123–1126 (1997).

    Article  CAS  Google Scholar 

  5. E. Castoldi, J. M. Brugge, G. A. Nicolaes, D. Girelli, G. Tans, J. Rosing, Impaired APC cofactor activity of factor V plays a major role in the APC resistance associated with the factor V Leiden (R506Q) and R2 (H1299R) mutations, Blood 103, 4173–4179 (2004).

    Article  PubMed  CAS  Google Scholar 

  6. M. Wilmer, C. Stocker, B. Buhler, B. Conell, A. Calatzis, Improved distinction of factor V wild-type and factor V Leiden using a novel prothrombin-based activated protein C resistance assay, Am J Clin Pathol. 122, 836–842 (2004).

    Article  PubMed  CAS  Google Scholar 

  7. R. J. Alexander, T. C. Detwiler, Quantitative adsorption of platelet glycoprotein G (thrombin-sensitive protein, thrombospondin) to barium citrate. Biochem. J. 217, 67–71 (1984).

    PubMed  CAS  Google Scholar 

  8. H. A. Donald, K. C. Ingham, Mechanism of precipitation of proteins by Polyethylene Glycol. J. Biol. Chem. 256, 12108–1211766 (1981).

    Google Scholar 

  9. J. A. Katzmann, M. E. Nesheim, L. S. Hibbard, K. G. Mann, Isolation of functional human coagulation factor V by using a hybridoma antibody. Proc. Natl. Acad. Sci. USA. 78, 162–166 (1981).

    Article  PubMed  CAS  Google Scholar 

  10. K. A. Kang, D. Ryu, W. M. Drohan and C. L. Orthner, Effect of matrices on affinity purification of protein C. Biotechnol Bioeng. 39, 1086–1096 (1992).

    Article  CAS  PubMed  Google Scholar 

  11. S. Rezania, D. G. Ahn, and K. A. Kang, Separation of protein C from Cohn fraction IV-1 by mini-antibody, Proceedings of the Annual 2005 ISOTT meeting. Adv. Exp. Med. Biol.: Oxygen Transport to Tissue XXVIII, 599, (Maguire, D.J., Bruley, D.F., Harrison, D.K., eds.), p. 125–132, 2007.

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Springer Science+Business Media, LLC

About this paper

Cite this paper

Rezania, S., Kang, K.A. (2008). Separation of Factor V Leiden Molecule, a Mutated Form of Factor V, from Plasma of Homozygous Patient. In: Kang, K.A., Harrison, D.K., Bruley, D.F. (eds) Oxygen Transport to Tissue XXIX. Advances In Experimental Medicine And Biology, vol 614. Springer, Boston, MA. https://doi.org/10.1007/978-0-387-74911-2_12

Download citation

Publish with us

Policies and ethics